Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells

International Journal of Cancer

Volumn 132, Issue 7, 2013, Pages 1525-1536

  Mir, Roser ^a   Tortosa, Avelina ^a   Martinez Soler, Fina ^a   Vidal, August ^a   Condom, Enric ^a   Pérez Perarnau, Alba ^a   Ruiz Larroya, Tatiana ^b   Gil, Joan ^a   Giménez Bonafé, Pepita ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Institute of Predictive and Personalized Medicine (IMPPC)   (Spain)

Author keywords

apoptosis; chemoresistance; Mdm2; Nut3a; ovarian cancer; Survivin

Indexed keywords

CISPLATIN; NUTLIN 3; PROTEIN MDM2; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG SENSITIZATION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; WILD TYPE;

ADENOCARCINOMA, MUCINOUS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; CISPLATIN; CYSTADENOCARCINOMA, SEROUS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENDOMETRIAL NEOPLASMS; FEMALE; FLOW CYTOMETRY; HUMANS; IMIDAZOLES; INHIBITOR OF APOPTOSIS PROTEINS; NEOPLASM GRADING; OVARIAN NEOPLASMS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MDM2; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84873079604     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27832     Document Type: Article

References (42)

1. Pignata S, Cannella L, Leopardo D, et al. Chemotherapy in epithelial ovarian cancer. Cancer Lett 2011; 303: 73-83.
2. Vasey PA,. Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies. Br J Cancer 2003; 89 (Suppl 3): S23-8.
3. Vogelstein B, Lane D, Levine AJ,. Surfing the p53 network. Nature 2000; 408: 307-10.
4. Vousden KH, Lu X,. Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2: 594-604.
5. Kigawa J, Sato S, Shimada M, et al. p53 gene status and chemosensitivity in ovarian cancer. Hum Cell 2001; 14: 165-71.
6. Chene P,. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer 2003; 3: 102-9.
7. Vassilev LT,. p53 activation by small molecules: application in oncology. J Med Chem 2005; 48: 4491-9.
8. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-8.
9. Tovar C, Rosinski J, Filipovic Z, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 2006; 103: 1888-93.
10. Kojima K, Konopleva M, Samudio IJ, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 2005; 106: 3150-9.
11. Cao C, Shinohara ET, Subhawong TK, et al. Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2. Mol Cancer Ther 2006; 5: 411-17.
12. Coll-Mulet L, Iglesias-Serret D, Santidrian AF, et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 2006; 107: 4109-114.
13. Villalonga-Planells R, Coll-Mulet L, Martinez-Soler F, et al. Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme. PLoS One 2011; 6: e18588.
14. Roh JL, Kang SK, Minn I, et al. p53-reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma. Oral Oncol 2011; 47: 8-15.
15. McWhinney SR, Goldberg RM, McLeod HL,. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 2009; 8: 10-16.
16. Eldering E, Spek CA, Aberson HL, et al. Expression profiling via novel multiplex assay allows rapid assessment of gene regulation in defined signalling pathways. Nucleic Acids Res 2003; 31: e153.
17. Liu T, Peng H, Zhang M, et al. A small molecule inhibitor of the Stat3 signaling pathway, enhances the chemosensitivity of laryngeal squamous cell carcinoma cells to cisplatin. Eur J Pharmacol 2010; 641: 15-22.
18. Chan WY, Cheung KK, Schorge JO, et al. Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am J Pathol 2000; 156: 409-17.
19. Powell CB, Fung P, Jackson J, et al. Aqueous extract of herba Scutellaria barbatae, a chinese herb used for ovarian cancer, induces apoptosis of ovarian cancer cell lines. Gynecol Oncol 2003; 91: 332-40.
20. Rouette A, Parent S, Girouard J, et al. Cisplatin increases B-cell lymphoma 2 expression via activation of protein kinase C and AKT2 in endometrial cancer cells. Int J Cancer 2012; 130: 1755-67.
21. Yasmeen A, Beauchamp MC, Piura E, et al. Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins. Gynecol Oncol 2011; 121: 492-8.
22. Luanpitpong S, Nimmannit U, Chanvorachote P, et al. Hydroxyl radical mediates cisplatin-induced apoptosis in human hair follicle dermal papilla cells and keratinocytes through Bcl-2-dependent mechanism. Apoptosis 2011; 16: 769-82.
23. Guha M, Altieri DC,. Survivin as a global target of intrinsic tumor suppression networks. Cell Cycle 2009; 8: 2708-10.
24. Liguang Z, Peishu L, Hongluan M, et al. Survivin expression in ovarian cancer. Exp Oncol 2007; 29: 121-5.
25. Wang Z, Xie Y, Wang H,. Changes in survivin messenger RNA level during chemotherapy treatment in ovarian cancer cells. Cancer Biol Ther 2005; 4: 716-19.
26. Uchida H, Tanaka T, Sasaki K, et al. Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol Ther 2004; 10: 162-71.
27. Altieri DC,. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003; 22: 8581-9.
28. Sullivan A, Syed N, Gasco M, et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 2004; 23: 3328-37.
29. Jacob NK, Cooley JV, Shirai K, et al. Survivin splice variants are not essential for mitotic progression or inhibition of apoptosis induced by doxorubicin and radiation. Oncol Targets Ther 2012; 5: 7-20.
30. Huang Y, Jin H, Liu Y, et al. FSH inhibits ovarian cancer cell apoptosis by up-regulating survivin and down-regulating PDCD6 and DR5. Endocr Relat Cancer 2011; 18: 13-26.
31. Kanwar JR, Shen WP, Kanwar RK, et al. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst 2001; 93: 1541-52.
32. Vivas-Mejia PE, Rodriguez-Aguayo C, Han HD, et al. Silencing survivin splice variant 2B leads to antitumor activity in taxane-resistant ovarian cancer. Clin Cancer Res 2011; 17: 3716-26.
33. Pennati M, Folini M, Zaffaroni N,. Targeting survivin in cancer therapy. Expert Opin Ther Targets 2008; 12: 463-76.
34. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-15.
35. Durinck S, Ho C, Wang NJ, et al. Temporal dissection of tumorigenesis in primary cancers. Cancer Discov 2011; 1: 137-43.
36. Cho KR, Ie MS,. Ovarian cancer. Annu Rev Pathol 2009; 4: 287-313.
37. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010; 363: 1532-43.
38. Kuo KT, Mao TL, Jones S, et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 2009; 174: 1597-601.
39. Cuatrecasas M, Villanueva A, Matias-Guiu X, et al. K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cancer 1997; 79: 1581-6.
40. Shen H, Maki CG,. Pharmacologic activation of p53 by small-molecule MDM2 antagonists. Curr Pharm Des 2011; 17: 560-8.
41. Secchiero P, Bosco R, Celeghini C, et al. Recent advances in the therapeutic perspectives of Nutlin-3. Curr Pharm Des 2011; 17: 569-77.
42. Yuan Y, Liao YM, Hsueh CT, et al. Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. J Hematol Oncol 2011; 4: 16.